International urology and nephrology · 2026
The effect of transperineal template prostate biopsy (TTPB) on selective serum biomarkers: a clinical-pilot observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dyer Marcus, Ella-Tongwiis Peter, Snyper Nana Yaa Frempomaa, Shergill Iqbal, Hughes Stephen Fôn
Аннотация
PURPOSE: Prostate biopsy is needed for diagnosing prostate cancer, the commonest cancer affecting men. Due to its lower rates of post-procedural infection compared to transrectal approaches, the use of transperineal approaches may increase. There is limited current evidence of serum biomarker changes following transperineal template prostate biopsy (TTPB) and their correlation with clinical outcomes.
METHODS: A within-group, repeated-measures observational study was employed. Venous blood samples were taken pre-TTPB (baseline) and at 30 and 240 min post-TTPB in 6 patients (median age 67 years, age range 63-76). The serum concentrations of 13 selective human growth factors were measured using the Luminex® Performance Assay. Patient medical notes were reviewed to assess clinical outcomes.
RESULTS: Following TTPB, significant increases were demonstrated in the serum concentration of PDGF-AA and TGF-alpha (p ≤ 0.05). Significant decreases were observed in the serum concentration of EGF and Flt3 ligand (p ≤ 0.05). There were no significant differences in the serum concentrations following TTPB in: CD40 Ligand, G-CSF, GRO-beta, IL-8, IL-33, MIP-3 beta, PDGF-AB/BB, TRAIL, and VEGF (p ≥ 0.05). There were no significant post-operative complications.
CONCLUSIONS: The significant increases in serum PDGF-AA and TGF-α, and significant decreases in serum EGF and Flt3 ligand could be explained by post-procedural inflammatory or paraneoplastic mechanisms. Further research into these biomarkers with larger cohorts may enable further understanding of their role pre- and post-operatively in TTPB and their correlation with clinical outcomes. This may be used to develop a clinical tool to predict or identify patients at risk of early post-TTPB complications.
METHODS: A within-group, repeated-measures observational study was employed. Venous blood samples were taken pre-TTPB (baseline) and at 30 and 240 min post-TTPB in 6 patients (median age 67 years, age range 63-76). The serum concentrations of 13 selective human growth factors were measured using the Luminex® Performance Assay. Patient medical notes were reviewed to assess clinical outcomes.
RESULTS: Following TTPB, significant increases were demonstrated in the serum concentration of PDGF-AA and TGF-alpha (p ≤ 0.05). Significant decreases were observed in the serum concentration of EGF and Flt3 ligand (p ≤ 0.05). There were no significant differences in the serum concentrations following TTPB in: CD40 Ligand, G-CSF, GRO-beta, IL-8, IL-33, MIP-3 beta, PDGF-AB/BB, TRAIL, and VEGF (p ≥ 0.05). There were no significant post-operative complications.
CONCLUSIONS: The significant increases in serum PDGF-AA and TGF-α, and significant decreases in serum EGF and Flt3 ligand could be explained by post-procedural inflammatory or paraneoplastic mechanisms. Further research into these biomarkers with larger cohorts may enable further understanding of their role pre- and post-operatively in TTPB and their correlation with clinical outcomes. This may be used to develop a clinical tool to predict or identify patients at risk of early post-TTPB complications.